Nebula Technology Lab Limited

Website

Company Bio

Visit website ↗Explore our full portfolio & program companies
Founders

LvlUp insightsGenerated from LvlUp’s portfolio data and the company’s own updates
Similar companies

More in the LvlUp portfolio

See all →

Building something ambitious?

LvlUp Ventures backs founders from first check to late stage.

Apply for funding
Kofi Osei-Ntem, Eduardo Salazar
Pre-Seed
MENA
AI, BioTech, FinTech, SaaS
What We Sell (Value Creation): COGENT3 creates value through a proprietary emergent AI drug discovery technology that helps pharma teams identify high-confidence molecule candidates from smaller assay datasets. It reduces the industry “Data Tax” associated with large-scale physical screening, heavy data infrastructure and brute-force model training. Our paid discovery pilots deliver actionable outputs: a ranked molecule shortlist, confidence scoring, prioritisation guidance for synthesis and testing, and a benchmarked proof point against existing methods or internal workflows. By improving molecule prioritisation earlier in the process, COGENT3 reduces wasted screening and condenses months of lead discovery into days or weeks. Who We Sell To: Our beachhead customers are organisations that need faster, lower-cost compound prioritisation, including: - Mid-sized pharma companies - Biotech companies - Regional pharma groups - Pharma VCs and venture studios - Product development partnerships (PDPs) and neglected-disease programmes These customers are most likely to benefit from earlier hit identification, lower screening burden and better prioritisation before committing to synthesis and testing. How Revenue Comes In (Value Capture): We capture value through a phased B2B commercial model:- Initial Revenue (Year 1): Paid discovery pilots with pharma and biotech customers, targeting $100k to $300k per engagement. Each pilot applies COGENT3 to a defined assay dataset and delivers ranked molecule candidates, confidence scoring and synthesis/testing prioritisation guidance. Our pre-seed milestone is to close three paid pilots to generate $300k to $900k in aggregated revenue. Our sales cycles run 4-10 weeks for biotechs and 3-6 months for pharma. Validation & PDP Co-Funding: Concurrently, we target $150k to $300k in grants and co-funding from PDPs and neglected-disease programmes. While these engagements take 3-6 weeks to agree to terms and 6-12 months for publication, they provide highly valuable in-kind access to compound libraries. Long-Term Revenue (Year 2+): Successful pilots are designed to convert into recurring revenue streams via licence agreements, CRO-style service agreements, or strategic partnerships.

Nebula Technology Lab is commercialising COGENT3, an emergent AI drug discovery technology that helps pharma teams identify high-confidence molecules from smaller assay datasets, reducing reliance on large-scale screening, heavy data infrastructure and brute-force model training.